Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 16
Submit an article Journal homepage
584
Views
12
CrossRef citations to date
0
Altmetric
Review

An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis

Zsuzsanna H. McMahana Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence[email protected]
View further author information
&
Elizabeth R. Volkmannb Division of Rheumatology, University of California, Los Angeles, CA, USAView further author information
Pages 2041-2056 | Received 01 Apr 2020, Accepted 06 Jul 2020, Published online: 17 Jul 2020

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Daniela A Moraes & Maria Carolina Oliveira. (2021) Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis. Journal of Blood Medicine 12, pages 951-964.
Read now

Articles from other publishers (11)

Corrado Campochiarro, Yannick Allanore, Yolanda Braun-Moscovici, Marco Matucci Cerinic & Alexandra Balbir-Gurman. (2023) Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?. Autoimmunity Reviews, pages 103439.
Crossref
L. A. Garzanova. (2023) Rituximab in the treatment of systemic sclerosis. Literature review. Rheumatology Science and Practice 61:4, pages 466-474.
Crossref
Anderson Rodrigues de Almeida, Andréa Tavares Dantas, Maria Eduarda de Oliveira Gonçalves, Charlotte Chêne, Mohamed Jeljeli, Sandrine Chouzenoux, Marine Thomas, Eudes Gustavo Constantino Cunha, Lilian David de Azevedo Valadares, João Victor de Melo Gomes, Simão Kalebe Silva de Paula, Marina Galdino da Rocha Pitta, Ivan da Rocha Pitta, Moacyr Jesus Barreto de Melo Rêgo, Michelly Cristiny Pereira, Angela Luzia Branco Pinto Duarte, Dulcineia Saes Parra Abdalla, Carole Nicco, Frédéric Batteux & Maira Galdino da Rocha Pitta. (2023) PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients. Inflammopharmacology.
Crossref
Anna C Falls, Catherine Wrigley & Surabhi A Khanna. (2023) Progressive Systemic Sclerosis With Negative Antinuclear Antibodies and Absence of Raynaud’s Phenomenon: A Case Report and Literature Review. Cureus.
Crossref
Diego Fernández-Lázaro, María Iglesias-Lázaro, Evelina Garrosa, Saray Rodríguez-García, David Jerves Donoso, Eduardo Gutiérrez-Abejón & Conrado Jorge-Finnigan. (2023) Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review. Medicina 59:2, pages 247.
Crossref
Malene Knarborg, Charlotte Hyldgaard, Elisabeth Bendstrup, Jesper Rømhild Davidsen, Anders Løkke, Saher Burhan Shaker & Ole Hilberg. (2023) Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data. Chronic Respiratory Disease 20.
Crossref
Rebekka Jerjen, Mandana Nikpour, Thomas Krieg, Christopher P. Denton & Amanda M. Saracino. (2022) Systemic sclerosis in adults. Part II: management and therapeutics. Journal of the American Academy of Dermatology 87:5, pages 957-978.
Crossref
Anna Kowalska-Kępczyńska. (2022) Systemic Scleroderma—Definition, Clinical Picture and Laboratory Diagnostics. Journal of Clinical Medicine 11:9, pages 2299.
Crossref
Peter Glynn, Sarah Hale, Tasmeen Hussain & Benjamin H. Freed. (2022) Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management. Frontiers in Cardiovascular Medicine 9.
Crossref
Bo Li, Junqing Yan, Jincheng Pu, Jianping Tang, Shuchang Xu & Xuan Wang. (2021) Esophageal Dysfunction in Systemic Sclerosis: An Update. Rheumatology and Therapy 8:4, pages 1535-1549.
Crossref
Nicholas A. Flavahan. (2021) New mechanism-based approaches to treating and evaluating the vasculopathy of scleroderma. Current Opinion in Rheumatology 33:6, pages 471-479.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.